For years, some of the most talked-about peptides in regenerative and longevity medicine have existed in a regulatory gray zone. A policy change this fall begins to clear a path — carefully, and with important limits worth understanding.
If you follow the peptide space, you've probably heard names like BPC-157 and TB-500 discussed for recovery, or MOTS-c and epitalon for metabolic and longevity support. Until recently, these couldn't be legally compounded for patients in the United States. On October 28, 2026, that began to change.
What actually changed
The U.S. Department of Health and Human Services issued a limited enforcement-discretion policy covering six specific peptides. In plain terms: the FDA has said it will not take enforcement action against state-licensed pharmacies and physicians who compound these six peptides — provided a detailed set of conditions is met.
The six peptides covered
| Peptide | Commonly discussed for |
|---|---|
| BPC-157 | Tissue repair, gut health, recovery |
| TB-500 | Soft-tissue recovery, inflammation |
| KPV | Inflammation, gut and skin support |
| MOTS-c | Metabolic and mitochondrial function |
| Semax | Cognitive and neurological support |
| Epitalon | Longevity and cellular aging |
The uses listed above reflect how these peptides are studied and discussed. They are not FDA-approved indications, and the evidence base varies considerably from one peptide to the next.
The conditions matter as much as the list
The policy only applies when strict requirements are met. A few that are worth knowing as a patient:
- 503A patient-specific compounding only. This applies to pharmacies and physicians compounding for an individual patient — not to large-scale manufacturing.
- Single ingredient only. Combination products — mixing two peptides in one vial — are excluded from the policy.
- Sourcing and quality standards. The raw material must come from an FDA-registered facility that meets manufacturing standards and provides a certificate of analysis.
- Clear labeling and safety reporting. Products must be labeled as compounded and not for resale, and serious adverse events must be reported to the FDA.
- It can be revisited. HHS has said it may revise or withdraw the policy if a safety or quality concern emerges.
Why a careful approach still matters
A path to legal compounding is not the same as a green light to use these peptides casually. Enforcement discretion is temporary and conditional. The underlying science still ranges from promising to preliminary depending on the compound, and these are still prescription therapeutics that require physician evaluation, appropriate candidacy, lab work, and monitoring.
Where PeplivMD stands. Our current offerings focus on well-established, FDA-approved and widely-used therapies — GLP-1 medications, sermorelin, tesamorelin, and PT-141. We are following the evolving regulatory landscape closely.
We intend to offer these additional peptides once they are available to us through compliant 503A compounding pharmacies, under the conditions the policy requires. As with every therapy we provide, each will be prescribed individually and evidence-first — only when it's clinically appropriate for the patient in front of us.
What happens next
The enforcement-discretion policy is an interim step, not the finish line. The FDA still has to complete formal notice-and-comment rulemaking before any of these peptides are permanently added to the compounding list — and that process includes further advisory-committee review. The written-comment period on the interim policy closed in mid-November 2026, and the broader rulemaking will unfold over the coming months.
We'll keep our patients and waitlist informed as things develop. If a peptide moves from "pending" to "appropriate to offer," you'll hear it from us with the clinical context to go with it.
Want updates as this develops?
Join the PeplivMD waitlist — we'll keep you posted as new therapies become available.
Join the WaitlistSources
- Foley & Lardner — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides
- Arnold & Porter — HHS Announces Draft Enforcement Discretion Policy
- NCPA — FDA Grants Enforcement Discretion to Compounding Six Peptides
- AJMC — 5 Things to Know About HHS's Interim Peptide Compounding Policy
This article is for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The peptides discussed are not FDA-approved, and the enforcement-discretion policy described is interim and subject to change. Nothing here is an offer to prescribe or a representation that any specific therapy is currently available through PeplivMD. Peptide therapies require a valid physician–patient relationship, individual evaluation, and prescription. PeplivMD is a program of New York CMG Medical PLLC.